Calciphylaxis Market

Calciphylaxis most commonly occurs in end-stage kidney patients and sometimes in earlier stages of chronic kidney disease. Almost always fatal, calciphylaxis causes chronic non-healing of wounds and affects up to 4% of all dialysis patients.

The Calciphylaxis Market is anticipated to reach USD 5.4 Billion by 2032 at 11.3% CAGR during the forecast period 2023-2032.

According to the National Kidney Foundation, close to 10% of the global population is afflicted with chronic kidney disease (CKD). CKD has been found to be among the top causes of death, and the increasing incidence of kidney disease is expected to resultant in the increasing occurrence of calciphylaxis. At present, there is no diagnostic test of the proper course of treatment for calciphylaxis, and instead, the condition relies on clinical check-ups and prevention. As such, the demand for the development of appropriate diagnostic and treatment options is expected to push the market forward. Reportedly, obesity and diabetes are among the more common risk factors which are highly prevalent today. These risk factors have inevitably impacted the incidence of kidney diseases, particularly in developed countries which are largely urban. Market players are expected to invest in R&D toward the development of therapeutic options for calciphylaxis which will undoubtedly offer the market with room for additional growth over the course of the projection period.

Challenges present in the market which impede growth include the high cost of existing treatment and the severe lack of effective therapeutic options targetted at calciphylaxis.

Major Key Players:

Some of the Calciphylaxis Market Players are Amgen Inc., Smith & Nephew plc, Medtronics, 3M, BSN Medical, ConvaTec Inc, Sanifit, and others.

Segment Analysis

The global calciphylaxis market is segmented on the basis of diagnosis, calciphylaxis treatment, and end user. On the basis of the diagnosis, the calciphylaxis market is further segmented into deep skin biopsies, blood tests, imaging, and others. The deep skin biopsies are further segmented into shave biopsy, punch biopsy, and excisional biopsy.

The blood tests is further segmented into serum parathormone levels, blood glucose levels, BUN (blood urea nitrogen), calcium levels, and others.

Imaging is further segmented into magnetic resonance imaging (MRI), CT scan, ultrasound, and others. On the basis of the applications, the market is segmented into intensive wound care, medication, therapy, clot-dissolving, and others.

Intensive wound care unit is further segmented into debridement, wet dressings, and others. The medication is further segmented into cinacalcet, sodium thiosulfate, steroids, and bisphosphonates. On the basis of end user, it is segmented into hospitals, clinics, medical research centers, academic institutes, and others.

Regional Analysis

The global calciphylaxis market consists of four regions the Americas, Europe, Asia Pacific, and the Middle East & Africa.

The Americas account for a major share of the market owing to the presence of patient population, well-developed technology, high healthcare expenditure and the presence of the leading players. Moreover, due to the high prevalence of end stage renal diseases (ESRD) on of the major cause of calciphylaxis in U.S. As per The Regents of the University of California, the rate of ESRD is increasing in the U.S. by 5% per year. The American calciphylaxis market is expected to reach USD 1,257 million by 2023 from USD 581.9 million in 2016.

Europe consists of two regions namely Western Europe and Eastern Europe. Western Europe consists of countries namely Germany, the U.K., France, Italy, Spain, and Rest of Western Europe. Increasing prevalence of cardiovascular calcification in ESRD patients is a key driver for the growth of this market in Europe. Moreover, increasing healthcare expenditure, rising research & development activities, awareness among patients about the treatment options supporting the market growth for calciphylaxis.

Asia Pacific consists of Japan, China, India, Australia, Republic of Korea, and rest of Asia Pacific. Increasing incidence of chronic kidney failure across Asia Pacific. Moreover, the growth of this segment is attributed to high population growth, increasing environmental pollution, and urbanization. Increasing incidence of calciphylaxis, improving healthcare infrastructure and rising awareness about the treatment process have spurred the growth of Asia Pacific region.  

On the other hand, the Middle East & Africa owns the minimum market share of the calciphylaxis market due to less development in the healthcare services such as new and advanced diagnosis & treatment methods in healthcare domain.

About Market Research Future

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 646 845 9312

Email: sales@marketresearchfuture.com